Accordingly, sorafenib combination with different compounds, such as EF24 or genistein, overcomes hypoxia-mediated sorafenib resistance in HCC through HIF-1α downregulation [20,48]. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.